IRF8 and lymphomagenesis

IRF8 和淋巴瘤发生

基本信息

项目摘要

The advent of massive parallel sequencing highlighted the genetic complexity of cancer, and unveiled the putative contribution of several unsuspected genes to the process of malignant transformation. These advances also indicated a need for the systematic examination of newly-found mutant genes as to determine whether they truly contribute to cancer pathogenesis, or simply represent innocuous variants irrelevant to the observed phenotype. Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is curable in only ~60% of cases. This clinical challenge is associated with the disease’s complex genetics, which include disruption of epigenetic modifiers, constitutive activation of the NF-κB pathway, and deregulation of B cell relevant transcription factors. The latter, can derive from chromosomal translocation, genomic amplification/deletions and somatic mutations. Recently, we developed an IGH-targeted capture/sequencing strategy and discovered novel aberrant gene fusions in DLBCL including the juxtaposing of IRF8 (interferon regulatory factor 8) to the IGH locus, t(14;16)(q32;q24), a prototypical model of transcription factor deregulation in B cell lymphomas. Independently, IRF8 was found to be somatically mutated in ~10% of DLBCL biopsies. Interestingly, close to 50% of the IRF8-mutant DLBCLs also have mutations in KMT2D, a histone methyltransferase that when inactivated enhances the lymphomagenic potential of other genetic lesions. IRF8, a member of the interferon family of transcription factors, is expressed in the germinal center (GC) where it directly influences the expression of several key regulators of the GC reaction, including BCL6, AICDA and PRDM1. The central objective of this proposal is to test the hypothesis that IRF8 is a bona fide oncogene in DLBCL, which can be deregulated by chromosomal translocation and somatic mutations. To advance this concept, we found that ectopic expression of IRF8 in DLBCL cell lines promotes a lymphomagenic profile characterized by induction of BCL6 and AICDA, suppression of PRDM1 and resistance to apoptosis. In addition, we generated preliminary data to show that the missense IRF8 mutants found in DLBCL are all gain-of-function. Lastly, we created a mouse with B cell restricted transgenic expression of Irf8. Building on our preliminary data, and on the availability of this novel animal model, we propose to address the following specific aims: 1) Determine the mechanism for Irf8 lymphomagenesis in a mouse model that mimics the IGH/IRF8 fusion found in human DLBCL; 2) Characterize in vivo the pro-lymphoma cooperation between the oncogenic Irf8 and the tumor suppressor Kmt2d; 3) Define the functional consequences of the somatic IRF8 mutations found in DLBCL. When this project is completed, we will show that IRF8 functions as an oncogene that cooperates with KMT2D loss for the development of DLBCL. We also expect to mechanistically link IRF8’s lymphomagenesis to the deregulation of BCL6, AICDA and PRDM1.
大规模平行测序技术的出现凸显了癌症基因的复杂性,并揭开了癌症的神秘面纱

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ricardo C Aguiar其他文献

Ricardo C Aguiar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ricardo C Aguiar', 18)}}的其他基金

Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10322194
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10117575
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
  • 批准号:
    10541234
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Oxidative stress and RNA methylation
氧化应激和 RNA 甲基化
  • 批准号:
    10330584
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Oxidative stress and RNA methylation
氧化应激和 RNA 甲基化
  • 批准号:
    10569629
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Post-Translational Control of TET Function in Lymphoma
淋巴瘤 TET 功能的翻译后控制
  • 批准号:
    10251482
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Post-Translational Control of TET Function in Lymphoma
淋巴瘤 TET 功能的翻译后控制
  • 批准号:
    10512054
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
  • 批准号:
    8974297
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
IRF8 and lymphomagenesis
IRF8 和淋巴瘤发生
  • 批准号:
    9235548
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
  • 批准号:
    8436704
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了